Aligos Therapeutics stock indicated to open at about $17.90, or 19% above IPO price

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Aligos Therapeutics Inc.

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply